A discount program caught in a legal dispute
Federal oversight of the 340B drug discount program is uncertain after a federal court rejected the government’s approach to one part of the program. The dispute concerns when manufacturers must provide discounted prices on orphan drugs and whether the Health Resources and Services Administration, or HRSA, has authority to impose those requirements.
The basic issue is straightforward, although the legal questions are not. Manufacturers must offer certain covered entities, including hospitals and community health centers, access to discounted drugs. Congress later created an exception for orphan drugs, which are specialized treatments developed for rare medical conditions. The Affordable Care Act included provisions related to that exception.
Federal regulators attempted to define how the exemption should operate through Federal Register documents from the Department of Health and Human Services. Under their rule, a manufacturer would not have to provide a 340B discount when an orphan drug was used to treat a rare disease. The discount would still be required if the same drug was prescribed for a secondary, non-orphan indication. As a result, the manufacturer’s obligation would depend on the condition being treated as well as on the product itself.
The Pharmaceutical Research and Manufacturers of America challenged the rule in federal court. The district court concluded that HRSA lacked the statutory authority to issue the type of legislative rule the agency had used to interpret the orphan drug exception. The decision rejected the specific pricing policy and the agency’s wider authority to establish binding requirements through that regulatory process, as discussed in the earlier article on the court blocking the 340B orphan drug rule.
The agency changes course
The ruling led federal officials to withdraw from a broader regulatory effort. HRSA withdrew its anticipated “Mega Rule,” an omnibus regulation that was still awaiting final federal review. The proposal was expected to address several disputed parts of the program, including patient eligibility and the requirements for contract pharmacies.
The agency did not give up its position on orphan drug pricing. Instead, it reissued the policy as an “interpretive rule.” A legislative rule establishes binding requirements under delegated regulatory authority. An interpretive rule is presented as guidance on how the agency understands existing law.
HRSA said the revised format would give covered entities direction without exceeding the limits identified by the court. Manufacturers rejected that explanation. They argued that the agency was trying to achieve indirectly what the court had already found it could not do directly.
The distinction between the two types of rules has practical effects and sits within the broader body of federal regulations collected in the Code of Federal Regulations. If the interpretive rule is treated as enforceable, hospitals, community health centers, and contract pharmacies may have to apply it when deciding whether a drug qualifies for 340B pricing. If it is only guidance, its immediate legal force is less certain. That difference affects purchasing decisions, internal compliance systems, and the price a covered entity expects to pay.
Why unsettled rules reach the checkout counter
The pharmaceutical industry responded with another lawsuit seeking to permanently block enforcement of the interpretive rule. Government officials argued that the case was premature because an interpretive rule is not a final agency action. Under that position, manufacturers would have to wait for an actual enforcement action before challenging the agency’s interpretation in court.
That position leaves the program in an interim state. Providers still need to purchase medicines while the courts consider whether the agency’s interpretation can be reviewed and enforced. Manufacturers must decide how to respond to a policy they view as unauthorized. Covered entities must prepare for the possibility that the policy will remain relevant or will be replaced.
The uncertainty also affects people buying medicine outside institutional purchasing systems. A cash patient comparing treatment costs needs a current price even though the wider market is shaped by rules and negotiations that may change. The current cost page addresses that immediate comparison. The policy question is larger: how should buyers make decisions when the rules governing discounts, eligibility, and enforcement remain unsettled?
Covered entities cannot wait for complete clarity. Hospitals and community health centers need to review their compliance protocols and be ready to adapt if federal guidance changes. Their review may include how they identify qualified patients, document eligibility, and manage relationships with contract pharmacies. HRSA has not yet delivered its replacement guidance, so those questions remain open.
The next regulatory test
HRSA has indicated that it plans to issue sweeping proposed guidance to replace the withdrawn omnibus rule. The proposal is expected to address long-running disputes over hospital eligibility metrics and the definition of a qualified patient.
The guidance will face scrutiny from providers and manufacturers. Providers may challenge provisions they consider too restrictive or difficult to administer. Manufacturers may challenge provisions they believe exceed HRSA’s authority or create pricing obligations that Congress did not authorize. The recent court decision makes the agency’s legal authority a central issue for any future rule.
The orphan drug dispute also shows how a rule can affect purchasing and compliance while its legal status remains contested. Providers must operate under current conditions, manufacturers must plan around uncertain obligations, and regulators must distinguish between explaining existing law and creating new requirements.
Until the courts define the limits of federal authority and HRSA issues replacement guidance, the 340B program will remain between unsettled policy and immediate operational demands, continuing the concerns described in the analysis of the uncertain future of the 340B Drug Discount Program. The outcome will affect how safety-net providers obtain medicines for vulnerable populations and how manufacturers participate in the program.